ClinicalTrials.gg
RecruitingNCT06386757Updated Feb 21, 2025

Comparison Between Nasal and Oropharyngeal Bleeding in Video Laryngoscopy and Direct Laryngoscopy for Nasal Intubation

An interventional study of Combined Video Laryngoscopy (VL) and Bougie and Combined Direct Laryngoscopy (DL) and Bougie in Maxillofacial Injuries, Nasal Bleeding and Intubation Complication, sponsored by Aswan University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Aswan University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The objective of this study is to compare the effectiveness and safety of video laryngoscopy versus direct laryngoscopy for nasal intubation in patients with maxillofacial fractures regarding less bleeding to oral and nasal structures, quicker intubation times, increased success rates for first intubation attempts, fewer uses of the Magill forceps and the less need for cervical spine extension

Read the detailed description

Maxillofacial fractures occur in a significant proportion worldwide and can occur as an isolated injury or in combination with other severe injuries including cranial, spinal, and upper and lower body injuries requiring prompt diagnosis with possible emergency interventions. The epidemiology of facial fractures varies with regard to injury type, severity, and cause and depends on the population studied.

Traumatic maxillofacial fractures are known to have difficulty in airway management due to anatomical and functional reasons. In many situations, treatment of facial fractures requires tracheal intubation. For fractures that involve occlusion, such as mandibular and Lefort fractures, oral intubation inhibits appropriate resolution of the occlusion. In these situations, nasotracheal intubation is indicated.

Direct laryngoscopic (DL) nasal intubations may be challenging if there is altered airway anatomy, difficulty in advancing the endotracheal tube through the glottis or in providers who are in training or those with less experience, even for patients with normal airway anatomy. The presence of cervical spine injury limit neck extension and makes airway manipulation more difficult. The use of Magill forceps is not always successful and is associated with endotracheal tube cuff damage and postoperative pharyngitis.

Video laryngoscopy (VL) is an adjunctive technique in anesthesia that utilizes a camera at the tip of the laryngoscope blade, which provides an indirect view of the glottis and surrounding structures during intubation displayed on a monitor. Use of video laryngoscopes has been shown to result in higher first intubation success, better laryngoscopic views, less mucosal trauma.

A bougie that is a long, stiff plastic wand is required to direct the tube to the glottis through manipulation through nasal route. bougie overcame the limitations of endotracheal tube direction and provided an advantage of rail-roading the tube over the bougie under vision leaving no possibility of trauma caused by direct or magill forceps tube manipulation.

Epistaxis is the most common complication encountered during nasotracheal (NT) intubation and may have serious consequences, such as lifethreatening bleeding and airway obstruction by aspirated blood. In addition, it may occur even when mucosal vasoconstriction, a lubricated tracheal tube and careful manipulation of the tube during insertion are employed.

02

Conditions studied

  • Maxillofacial Injuries
  • Nasal Bleeding
  • Intubation Complication

Keywords

  • nasal intubation
  • videolaryngscopy
  • direct laryngscopy
  • bogie stylet
03

In context

Maxillofacial Injuries

22 studies on the registry are indexed under Maxillofacial Injuries; 7 are open to participants now.

This study's planned enrollment of 64 is above the median of 28 across 10 interventional studies indexed under Maxillofacial Injuries.

Browse Maxillofacial Injuries studies →

Lead sponsor

Aswan University is the lead sponsor of 47 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who will undergo maxillofacial surgeries with nasotracheal intubation..
  • /II patients.
  • \<35

Exclusion criteria

Exclusion Criteria:

  • Having bleeding diathesis and abnormal (PT), Partial Thromboplastin Time (PTT), or counts.
  • Local causes of bleeding as adenoid
  • On medications that alter blood coagulation as anticoagulants and antiplatlets.
  • Patients in which either intubation failed on both nostrils or where intubation was only possible with a tube smaller than 6.0 mm internal diameter(ID).
  • Anticipated difficult airways.
  • /IV.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Group Ι Combined Video Laryngoscopy (VL) and Bougie

    Group Ι Combined Video Laryngoscopy (VL) and Bougie: Nasal intubation will be performed using a video laryngoscope and a bougie.

  • Active comparator
    Group ΙI Direct Laryngoscopy (DL) and Bougie :

    Nasal intubation will be performed using a traditional direct laryngoscope and a bougie.

    Procedure: Combined Direct Laryngoscopy (DL) and Bougie

Interventions

  • ProcedureCombined Video Laryngoscopy (VL) and Bougie

    To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.

  • ProcedureCombined Direct Laryngoscopy (DL) and Bougie

    To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation

06

What researchers measure

Primary outcomes

  1. Incidence of nasal and oropharyngeal bleeding

    Incidence of nasal and oropharyngeal bleeding using Fromme's ordinal scale which is used for assessment of the surgical field quality( V Rajanigandha, et al. 2023),we will modify this scale to evaluate airway as follows : 0- No bleeding (virtually bloodless field) 1. Minimal bleeding ( not a nuisance to vision , no suctioning required) 2. Mild bleeding (a nuisance to vision but does not compromises laryngeal tube insertion, occasional suctioning required ) 3. Moderate bleeding (slightly compromises laryngeal tube insertion, frequent suctioning required) 4. Severe bleeding (significantly compromises laryngeal tube insertion, frequent suctioning required) 5. Massive bleeding (cannot insert laryngeal tube, constant suctioning required)

    Time frame: Through study completion, average 60 minutes at 5, 15, 30 minutes

Secondary outcomes

  1. Time of successful intubation, defined as the time from removal of mask ventilation and beginning of bougie insertion until inflation of tube cuff

    Time of successful intubation, defined as the time from removal of mask ventilation and beginning of bougie insertion until inflation of tube cuff

    Time frame: Within minutes

  2. Overall rate of first trial success.

    Overall rate of first trial success.

    Time frame: Within minutes

  3. The use of magill forceps

    The use of magill forceps

    Time frame: Within minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nedrud SM, Baasch DG, Cabral JD, McEwen DS, Dasika J. Combined Video Laryngoscope and Fiberoptic Nasal Intubation. Cureus. 2021 Nov 11;13(11):e19482. doi: 10.7759/cureus.19482. eCollection 2021 Nov. PubMed 34912623 ↗
  • Kumar P, Sharma J, Johar S, Singh V. Guiding Flexible-Tipped Bougie Under Videolaryngoscopy: An Alternative to Fiberoptic Nasotracheal Intubation in Maxillofacial Surgeries. J Maxillofac Oral Surg. 2020 Jun;19(2):324-326. doi: 10.1007/s12663-020-01327-w. Epub 2020 Jan 24. PubMed 32346248 ↗
  • Prasant MC, Kar S, Rastogi S, Hada P, Ali FM, Mudhol A. Comparative Study of Blood Loss, Quality of Surgical Field and Duration of Surgery in Maxillofacial Cases with and without Hypotensive Anesthesia. J Int Oral Health. 2014 Nov-Dec;6(6):18-21. PubMed 25628477 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jan 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 26, 2024
StartActual
Jun 1, 2024
Primary completionActual
Jan 1, 2025
CompletionEst.
Mar 1, 2025
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06386757
Lead sponsor
Aswan University
Responsible party
Soudy Salah Hammad (Lecturer of anesthesia and surgical intensive care, Aswan University) — Principal investigator
First posted
Apr 26, 2024
Start date
Jun 1, 2024
Primary completion
Jan 1, 2025
Completion
Mar 1, 2025 (estimated)
Last update
Feb 21, 2025

Study contacts

Soudy S Hammad, MD
Contact
soudi.salah@aswu.edu.eg
+201014761523
Mohammed E Yahia, MSc
Contact
01125257916
Mohammed A Alazhary, MD
principal investigator · Aswan University
Ayman M Eldemrdash, MD
principal investigator · Aswan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion